Trulieve anticipates at least $225M in 2026 operating cash flow while raising capex outlook to $95M (NYSE:TRLV)

Trulieve (TRLV) Q2 2026 earnings call highlights: NYSE uplisting, 280E repeal impact, guidance, cash flow, and Texas/Georgia growth—read now.

Trulieve anticipates at least $225M in 2026 operating cash flow while raising capex outlook to $95M (NYSE:TRLV) | Seeking Alpha

Earnings Call Insights: Trulieve Cannabis Corp. (TRLV) Q2 2026

Management View

“We are thrilled to report second quarter results for the first time as a company listed on the New York Stock Exchange.” (Founder, Chairman & CEO Kimberly Rivers)

“In

Seeking Alpha's Disclaimer:

This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.

Is this happening to you frequently? Please

report it on our feedback forum.

If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.

Search field

Entering text into the input field will update the search result below

Quick Insights

How does NYSE listing and deconsolidation affect Trulieve's financial outlook?

The NYSE listing and Harvest deconsolidation resulted in changes to consolidated revenue, a significant one-time net loss for Q2 due to the deconsolidation, and guidance transitioning to a medical-only basis; Trulieve expects continued strong cash flow and investments focused on medical operations.

What are the growth and revenue expectations for Trulieve's medical marijuana business, especially in Georgia and Texas?

Trulieve forecasts Q3 revenue comparable to $222 million (medical-only basis) and full-year operating cash flow of at least $225 million, with growth opportunities in Georgia and Texas contingent on resolving product shortages, expanding supply, and regulatory approvals.

What near-term risks could impact Trulieve's operations and financial performance?

Key near-term risks include product shortages in Georgia, variable gross margins due to product/market mix, and regulatory timing in Texas, as execution depends on supply, demand ramp, and state licensing processes.

Recommended For You

More

Trending News

See More

»